This pilot study investigates the use of autologous dendritic cells (DCs) pulsed with tumor-specific idiotyp protein to stimulate antitumor immunity in patients with follicular B-cell lymphoma. Four patients received a series of three or four infusions of antigen-pulsed DCs, followed by subcutaneous injections of soluble antigen two weeks later. All patients developed measurable antitumor cellular immune responses, with one patient experiencing complete tumor regression, another partial regression, and a third resolving all evidence of disease. The study highlights the potential of this approach to induce strong and uniform antitumor immune responses, which could be further enhanced by additional vaccinations. The results suggest that antigen-pulsed DCs represent a powerful new vaccine capable of inducing cellular immune responses against weak antigens such as tumor proteins, with potential applications in the treatment of B-cell malignancies.This pilot study investigates the use of autologous dendritic cells (DCs) pulsed with tumor-specific idiotyp protein to stimulate antitumor immunity in patients with follicular B-cell lymphoma. Four patients received a series of three or four infusions of antigen-pulsed DCs, followed by subcutaneous injections of soluble antigen two weeks later. All patients developed measurable antitumor cellular immune responses, with one patient experiencing complete tumor regression, another partial regression, and a third resolving all evidence of disease. The study highlights the potential of this approach to induce strong and uniform antitumor immune responses, which could be further enhanced by additional vaccinations. The results suggest that antigen-pulsed DCs represent a powerful new vaccine capable of inducing cellular immune responses against weak antigens such as tumor proteins, with potential applications in the treatment of B-cell malignancies.